M2 Presswire - Novartis receives FDA approvable letter for Diovan (valsartan) for the treatment of heart failure in patients not on an ACE inhibitor.
M2 PRESSWIRE-25 October 2001-NOVARTIS: Novartis receives FDA approvable letter for Diovan (valsartan) for the treatment of heart failure in patients not on an ACE inhibitor (C)1994-2001 M2 COMMUNICATIONS LTD RDATE:25102001 East Hanover, New Jersey / Basel, Switzerland — Novartis announced today that it has received an “approvable” letter from the US Food and Drug Administration (FDA) for Diovan (valsartan) for the treatment of heart failure in patients not on an ACE inhibitor.
Related Results
DiovanDiovanDiovan dosesFDA approves DiovanNew indication for diovan
Final approval is contingent on further analysis of existing data or possibly the …
Read the rest of this article with a Free Trial at HighBeam Research.
